SuperworthTranscode Therapeutics market cap RNAZ
Share price times shares outstanding: what the whole company sells for, since 2021.
- Today, Oct 23, 2026
- $30M
- Highest close in our data
- $48.6M
- Aug 2026
Transcode Therapeutics is worth $30M at the close on Oct 23, 2026, at $1.77 a share.
That is up 168% over the last year and up 17% over five years.
Its highest close in our data was $48.6M in Aug 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $30M | $3.1M | $48.6M | +370% |
| 2025 | $6.4M | $211.3K | $12.7M | +375% |
| 2024 | $1.3M | $224.3K | $8.5M | −42% |
| 2023 | $2.3M | $462.3K | $6.9M | −62% |
| 2022 | $6.1M | $3.3M | $27.4M | −73% |
| 2021 | $22.9M | $22M | $33.1M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Transcode Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| RNAZTranscode Therapeutics | $30M |
| ATNMActinium Pharmaceuticals | $47.8M |
| SPROSpero Therapeutics | $64.6M |
| LFVNLifevantage | $73.4M |
| NATRNatures Sunshine Products | $213.8M |
| Peer median | $69M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Transcode Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.